Combination of CD137 antibody and CTLA-4 antibody for the treatment of proliferative diseases
Compositions and methods are disclosed which are useful of the treatment and prevention of proliferative disorders.
1. A method for diminishing the incidence or severity of immunotherapy-dependent colitis associated with anti-CTLA4 therapy comprising administering to a mammal in need thereof a combination comprising the sequential administration of a therapeutically effective amount of an agonistic CD137 antibody, followed by the administration of a therapeutically effective amount of an antagonistic CTLA-4 antibody, wherein the incidence or severity of immunotherapy-dependent colitis associated with anti-CTLA4 therapy is diminished.
2. The method according to claim 1 comprising an interstitial period in between said administrations.
3. The method according to claim 2 wherein said interstitial period is one day.
4. The method according to claim 2 wherein said interstitial period is between 18 to 24 hours.
5. The method according to claim 2 wherein said interstitial period is between 12 to 18 hours.
6. The method according to claim 2 wherein said interstitial period is less than 12 hours.
7. The method according to claim 1 wherein the antagonistic CTLA-4 antibody is ipilimumab.
8. The method according to claim 1 wherein the antagonistic CTLA-4 antibody is tremelimumab.